ACOGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Alpha Cognition Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$8.50+0.31 (+3.79%)

Close on Oct 19, 2026

Market cap: $185.08M
P/E (TTM): –
Dividend yield: –

Alpha Cognition Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31
Revenue	10	–	–
Cost of Revenue	0.60	–	–
Gross Profit	9.62	–	–
Research & Development	1.87	3.92	4.88
Selling, General & Admin	29	8.01	–
General & Administrative	–	7.94	5.05
Advertising Expenses	0.38	0.10	0.02
Operating Expenses	33	12	9.94
Total Costs & Expenses	33	12	–
Operating Income	-23	-12	-9.94
Interest Expense	–	0.11	0.02
Interest & Investment Income	–	0.16	0.01
Other Non-Operating Income	1.99	-2.78	-3.83
Gain (Loss) on Sale of Assets	-0.02	–	–
Net Income	-21	-15	-14
Net Income to Common	-21	-15	-14
EPS (Basic)(per share)	-1.17	-2.04	-3.84
EPS (Diluted)(per share)	-1.18	-2.04	-3.84
Shares Outstanding (Basic, Weighted)(shares)	18	7.25	3.59
Shares Outstanding (Diluted, Weighted)(shares)	18	7.25	3.59
EBITDA	-23	-12	-9.85
Provision for Credit Losses	–	0.06	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 92.7%
Operating margin: -190.6%
Net margin: -153.6%
Return on equity, FY2025: -40.7%

Financial strength

Current ratio: 9.03
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 645.3%

Valuation

P/E ratio: –
Price to sales: 12.13
Price to book: 3.49
Dividend yield: –